Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Cortes on the Future of Ponatinib in CML Treatment

January 18th 2021

Jorge E. Cortes, MD, discusses the future of ponatinib in the treatment of patients with chronic myeloid leukemia.

DREAMM-2 Trial Regimen Safety Profile

January 18th 2021

DREAMM-2 Trial Efficacy Data and Recent FDA Approval

January 18th 2021

Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

January 18th 2021

Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

January 18th 2021

FDA Approves Subcutaneous Daratumumab Plus VCd for Newly Diagnosed Light-Chain Amyloidosis

January 15th 2021

January 15, 2021 - The FDA has approved daratumumab and hyaluronidase-fihj, a subcutaneous formulation of daratumumab, for use in combination with bortezomib, cyclophosphamide, and dexamethasone in the treatment of patients with newly diagnosed light-chain amyloidosis.

Molecular Testing in Community Practices

January 15th 2021

Role of Molecular Testing in AML

January 15th 2021

Rapid Readouts: Phase 2 Study of Navitoclax in High-Risk Myelofibrosis

January 15th 2021

Dr. Kumar on Understanding the Safety Profiles of Combination Therapies in Multiple Myeloma

January 15th 2021

Shaji K. Kumar, MD, discusses the importance of understanding the safety profiles of combination therapies in multiple myeloma.

Dr. Olin on the Rationale to Evaluate Menin Inhibitors in AML

January 14th 2021

Rebecca L. Olin, MD, MSCE, discusses the rationale to evaluate menin inhibitors in acute myeloid leukemia.

Dr. Shah on the Safety of a Novel Dual-Targeted CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 14th 2021

Nirav Shah, MD, MCW, discusses the safety profile of an anti-CD20/anti-CD19 CAR T-cell therapy under investigation in the treatment of patients with non-Hodgkin lymphoma.

FDA Approves Crizotinib for Pediatric and Young Adult ALK+ Anaplastic Large Cell Lymphoma

January 14th 2021

January 14, 2021 - The FDA has approved crizotinib for the treatment of pediatric patients 1 year of age and older and young adults with ALK-positive relapsed or refractory, systemic anaplastic large cell lymphoma.

Immunotherapy Inches Forward in Development of Myeloid Malignancies

January 14th 2021

Amer Zeidan, MD, MHS, discusses how survival for patients with acute myeloid leukemia and myelodysplastic syndrome remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date.

INN Melphalan Flufenamide–DEX for Older Patients With RRMM

January 14th 2021

RRMM & High-Risk Cytogenetics: INN Melphalan Flufenamide/DEX

January 14th 2021

RRMM: INN Melphalan Flufenamide/DEX and Extramedullary Disease

January 14th 2021

HORIZON vs MAMMOTH Explored in R/R Multiple Myeloma

January 14th 2021

INN Melphalan Flufenamide in Triple-Class Refractory/Relapsed MM

January 14th 2021

Treatment Advances in Triple-Class Refractory/Relapsed Myeloma

January 14th 2021